Type 2 Diabetes Mellitus
📧 Sign up to get email alerts when something new happens for Type 2 Diabetes Mellitus.
Sign up freeTop drugs studied for this disease
-
FDA label_change · 2026-08-11FDA Approved: GLIPIZIDE AND METFORMIN HYDROCHLORIDE — Supplemental Application (Zydus Pharmaceuticals USA Inc.)
FDA supplemental approval for Glipizide and Metformin hydrochloride combination product (Zydus Pharmaceuticals USA Inc.).
-
FDA label_change · 2026-08-11FDA Approved: METFORMIN HYDROCHLORIDE — Supplemental Application (Granules Pharmaceuticals Inc.)
A supplemental application for metformin hydrochloride was approved, typically reflecting a formulation change, labeling update, or manufact…
-
FDA label_change · 2026-08-11FDA Approved: METFORMIN HYDROCHLORIDE — Supplemental Application (ALIGNSCIENCE PHARMA)
FDA supplemental application for metformin hydrochloride submitted by AlignScience Pharma; indicates a label change or addition related to a…
-
FDA label_change · 2026-08-07FDA Approved: REPAGLINIDE — Supplemental Application (Macleods Pharmaceuticals Limited)
Supplemental approval for REPAGLINIDE filed by Macleods Pharmaceuticals Limited.
-
FDA label_change · 2025-10-24FDA Approved: GLYXAMBI — Supplemental Application (Boehringer Ingelheim Pharmaceuticals, Inc.)
FDA approved a supplemental application for GLYXAMBI (empagliflozin and linagliptin) submitted by Boehringer Ingelheim Pharmaceuticals, Inc.…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA label_change · 2025-10-24FDA Approved: SYNJARDY — Supplemental Application (Boehringer Ingelheim Pharmaceuticals, Inc.)
FDA approves a supplemental application for SYNJARDY (empagliflozin and metformin hydrochloride) to update the product labeling.
-
FDA label_change · 2025-06-20FDA Approved: GLYBURIDE-METFORMIN HYDROCHLORIDE — Supplemental Application (Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.)
FDA notes a supplemental application for glyburide/metformin hydrochloride (Heritage Pharmaceuticals d/b/a Avet Pharmaceuticals Inc.) to upd…
-
FDA label_change · 2025-05-28FDA Approved: BYETTA — Supplemental Application (AstraZeneca Pharmaceuticals LP)
The FDA entry documents a supplemental application for BYETTA (exenatide) submitted by AstraZeneca.
-
FDA label_change · 2024-01-19FDA Approved: INVOKAMET — Supplemental Application (Janssen Pharmaceuticals, Inc.)
The FDA approved a supplemental labeling application for INVOKAMET (canagliflozin and metformin hydrochloride) filed by Janssen Pharmaceutic…
-
FDA label_change · 2022-07-01FDA Approved: LEVEMIR — Supplemental Application (Novo Nordisk)
FDA approves a supplemental application for LEVEMIR (insulin detemir) from Novo Nordisk. The action updates the product labeling.
-
FDA label_change · 2022-03-21FDA Approved: GLYXAMBI — Supplemental Application (Boehringer Ingelheim Pharmaceuticals, Inc.)
The FDA approved a supplemental application for GLYXAMBI (empagliflozin and linagliptin) from Boehringer Ingelheim Pharmaceuticals, resultin…
-
FDA label_change · 2021-09-17FDA Approved: SEGLUROMET — Supplemental Application (Merck Sharp & Dohme LLC)
FDA approved a supplemental application for Segluromet (ertugliflozin and metformin HCl) submitted by Merck to update the product labeling.
-
FDA label_change · 2021-06-11FDA Approved: SYNJARDY — Supplemental Application (Boehringer Ingelheim Pharmaceuticals, Inc.)
FDA approved a supplemental application for Synjardy (empagliflozin and metformin hydrochloride) submitted by Boehringer Ingelheim Pharmaceu…
-
FDA label_change · 2020-07-29FDA Approved: WELCHOL — Supplemental Application (Cosette Pharmaceuticals, Inc.)
FDA approved a supplemental application for Welchol (colesevelam hydrochloride) to update the labeling and potentially expand its approved u…
-
FDA label_change · 2020-03-30FDA Approved: GLYXAMBI — Supplemental Application (Boehringer Ingelheim Pharmaceuticals, Inc.)
FDA approved a supplemental application for Glyxambi (empagliflozin and linagliptin), updating the product labeling.
-
FDA label_change · 2020-01-27FDA Approved: INVOKAMET XR — Supplemental Application (Janssen Pharmaceuticals, Inc.)
FDA approved a supplemental labeling change for INVOKAMET XR, the fixed-dose combination of canagliflozin and metformin hydrochloride from J…
-
FDA label_change · 2020-01-24FDA Approved: STEGLUJAN — Supplemental Application (Merck Sharp & Dohme LLC)
FDA overview of a supplemental application for Steglujan (ertugliflozin and sitagliptin) from Merck Sharp & Dohme LLC.
-
FDA label_change · 2020-01-24FDA Approved: SYNJARDY — Supplemental Application (Boehringer Ingelheim Pharmaceuticals, Inc.)
FDA approved a supplemental application for SYNJARDY (empagliflozin and metformin hydrochloride) submitted by Boehringer Ingelheim to update…
-
FDA label_change · 2019-07-03FDA Approved: GLYXAMBI — Supplemental Application (Boehringer Ingelheim Pharmaceuticals, Inc.)
FDA approved a supplemental application for GLYXAMBI (empagliflozin and linagliptin) from Boehringer Ingelheim Pharmaceuticals, Inc., updati…
-
FDA label_change · 2019-06-17FDA Approved: LIRAGLUTIDE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approves a supplemental application for liraglutide from Teva Pharmaceuticals USA, Inc., resulting in changes to the product labeling.
-
FDA label_change · 2018-11-07FDA Approved: METFORMIN HYDROCHLORIDE — Supplemental Application (Oceanside Pharmaceuticals)
The FDA has approved a supplemental application for metformin hydrochloride filed by Oceanside Pharmaceuticals. The submission status is AP.
-
FDA label_change · 2018-10-29FDA Approved: INVOKANA — Supplemental Application (Janssen Pharmaceuticals, Inc.)
The FDA approved a supplemental application for INVOKANA (canagliflozin) from Janssen Pharmaceuticals, Inc. to update the drug's labeling.
-
FDA label_change · 2018-10-26FDA Approved: STEGLUJAN — Supplemental Application (Merck Sharp & Dohme LLC)
The FDA approved a supplemental application for Steglujan (ertugliflozin and sitagliptin) from Merck Sharp & Dohme LLC.
-
FDA label_change · 2018-03-06FDA Approved: STEGLUJAN — Supplemental Application (Merck Sharp & Dohme LLC)
The FDA approved a supplemental application for Steglujan (ertugliflozin and sitagliptin) from Merck Sharp & Dohme LLC, indicating changes t…
-
FDA label_change · 2017-12-21FDA Approved: ACTOPLUS MET — Supplemental Application (Takeda Pharmaceuticals America, Inc.)
The FDA approved a supplemental application for ACTOPLUS MET (pioglitazone and metformin hydrochloride) filed by Takeda to update the drug's…